- $6.41m
- $9.52m
- $4.92m
- 54
- 41
- 65
- 52
Annual income statement for Stemtech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 August 31st | 2020 August 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 15 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 4.32 | 4.56 | 4.92 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 3.3 | 3.4 | 3.92 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.02 | 0.019 | 7.53 | 5.78 | 8.33 |
| Operating Profit | -0.02 | -0.019 | -3.21 | -1.22 | -3.41 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.034 | -0.034 | -7.11 | -8.54 | -5.43 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.034 | -0.034 | -7.11 | -8.63 | -5.43 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.034 | -0.034 | -7.08 | -8.54 | -5.43 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.034 | -0.034 | -7.08 | -8.54 | -5.43 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.063 | -0.064 | -0.188 | -0.239 | -0.075 |
| Dividends per Share |